We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current MXCT market cap is 428.51M. The company's latest EPS is USD -0.3664 and P/E is -11.30.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.04M | 8M | 15.67M | 11.34M | 10.43M |
| Operating Income | -13.07M | -13.95M | -8.1M | -12.28M | -11.97M |
| Net Income | -10.51M | -11.25M | -5.28M | -9.53M | -9.38M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 21.62M | 26.17M | 33.89M | 44.26M | 41.29M |
| Operating Income | -12.42M | -11.06M | -18.19M | -27.36M | -48.3M |
| Net Income | -12.9M | -11.82M | -19.08M | -23.57M | -37.92M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 271.2M | 266.73M | 268.27M | 257.93M | 251.5M |
| Total Liabilities | 30.22M | 33.35M | 36.11M | 31.57M | 30.24M |
| Total Equity | 240.98M | 233.38M | 232.17M | 226.36M | 221.26M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 29.99M | 51.78M | 284.12M | 286.65M | 268.27M |
| Total Liabilities | 16.38M | 18.56M | 21.22M | 32.69M | 36.11M |
| Total Equity | 13.6M | 33.23M | 262.9M | 253.97M | 232.17M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -14.43M | -22.67M | -21.69M | -10.56M | -15.4M |
| Investing | 56.31M | 59.12M | 54.98M | -14.4M | 4.99M |
| Financing | 1.61M | 1.65M | 2.14M | 703k | 1.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -8.8M | -8.78M | -10.68M | -14.78M | -21.69M |
| Investing | 455k | -16.58M | -195.01M | -24.82M | 54.98M |
| Financing | 12.31M | 28.9M | 234.72M | 2.89M | 2.14M |
| Market Cap | 428.51M |
| Price to Earnings Ratio | -11.30 |
| Price to Sales Ratio | 10.38 |
| Price to Cash Ratio | 9.21 |
| Price to Book Ratio | 1.85 |
| Dividend Yield | - |
| Shares Outstanding | 103.5M |
| Average Volume (1 week) | 460.39k |
| Average Volume (1 Month) | 684.19k |
| 52 Week Change | -17.20% |
| 52 Week High | 5.545 |
| 52 Week Low | 3.165 |
| Spread (Intraday) | 0.49 (11.69%) |
| Company Name | MaxCyte Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.maxcyte.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
